Tag: osé
OSE Immunotherapeutics: new European patent – 05/02/2022 at 08:46
(AOF) – OSE Immunotherapeutics has announced that the European Patent Office (EPO) has granted a new patent that enhances the protection of CLEC-1 (among CLR – C-type lectin receptors), its…
OSE Immuno: a European patent for CLEC-1
(CercleFinance.com) – OSE Immunotherapeutics announces that the European Patent Office (EPO) has granted a new patent which strengthens the protection of CLEC-1, its new myeloid checkpoint inhibitor target, and its…
OSE Immuno: a European patent for CLEC-1 – 05/02/2022 at 09:45
(CercleFinance.com) – OSE Immunotherapeutics announces that the European Patent Office (EPO) has granted a new patent which strengthens the protection of CLEC-1, its new myeloid checkpoint inhibitor target, and its…
Ose Immunotherapeutics: loss of sand but revenue up – 03/31/2022 at 08:58
(AOF) – In 2021, OSE Immunotherapeutics posted a net loss of 16.85 million euros compared to a loss of 16.555 million in 2020. The biotech’s current operating loss stood at…
Unusual volumes on the stock market today: Ose Immunotherapeutics
During this trading session on Thursday March 24, 2022, abnormal trading volumes were detected on the French market. Today, it is the Ose Immunotherapeutics share that stands out, with trading…
OSE Immunotherapeutics receives first US patent grant for OSE-279, an anti-PD1 monoclonal antibody, and its use in the treatment of cancer – 03/21/2022 at 18:00
• A grant agreement issued by the United States Patent and Trademark Office • This new patent will protect OSE-279 until 2039 Nantes, France – March 21, 2022, 6:00 p.m.…
Ose immuno: Agreement for a patent in the USA
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
OSE Immunotherapeutics: agreement for a patent in the USA – 03/21/2022 at 18:12
(CercleFinance.com) – OSE Immunotherapeutics announces that the United States Patent and Trademark Office (USPTO) has granted a first agreement to grant a patent relating to OSE-279, an anti-PD1 monoclonal antibody,…
OSE Immuno announces positive long-term memory response with CoVepiT
By Hector Chaunu Published on 03/16/2022 at 6:17 p.m. Photo credit © Reuters …
Abnormal volumes on the Paris Stock Exchange: Ose Immunotherapeutics
During this trading session on Monday March 14, 2022, abnormal trading volumes were detected on the French market. Today, it is the Ose Immunotherapeutics share that stands out, with trading…
OSE: ‘encouraging’ signals in phase 1 study
(CercleFinance.com) – OSE Immunotherapeutics presented on Wednesday, in collaboration with its German partner Boehringer Ingelheim, the first results of a phase 1 clinical study concerning its BI 765063 antibody in…
OSE Immuno: appointment of Alexandre Lebeaut as independent director
By Hector Chaunu Published on 02/18/2022 at 6:18 p.m. Photo credit © Reuters …